ASCO 2025 Press Releases Johnson & Johnson Leads with First PARP Inhibitor Combo to Improve Efficacy in Patients with HRR-altered mCSPC ImmunityBio Receives FDA Expanded Access Authorization for ...

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...

AUA 2025 Upper Tract Urothelial Carcinoma AUA 2025: Phase II Study of Tislelizumab as Neoadjuvant Treatment for Cisplatin-Ineligible High Risk Upper Tract Urothelial Carcinoma AUA 2025: Long-Term ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Tumor suppressor genes play a critical role in prostate cancer progression, with alterations in PTEN, TP53, and RB1 representing some of the most clinically significant genomic events. These ...

Matthew Cooperberg speaks with Martin Gleave about GUNS, a neoadjuvant adaptive umbrella trial for men with high-volume, high-grade prostate cancer. Now at 280 patients enrolled, GUNS sequences needle ...

Peyronie's disease (PD) is an acquired fibrotic condition of the tunica albuginea that is characterized by penile curvature, deformity, pain, and impaired sexual function. PD is prevalent among all ...

The 2026 PSMA & Beyond conference featured a session on challenges of radioligand therapy and a presentation by Dr. Inès Camille Azrour discussing renal toxicity associated with PSMA targeted therapy.

The 2026 PSMA & Beyond conference featured a challenges of radioligand therapy session and a presentation by Dr. Daniel Childs discussing long term marrow toxicity rates and risk factors. 177 ...

The 2026 PSMA & Beyond conference featured a session on challenges of radioligand therapy and a presentation by Dr. Michael Hofman discussing the expansion of the theranostic dream. Only 8 years ago, ...

Dr. Morris then discussed the PCWG4 Rule of 5 for defining radiographic progression free survival in the post-flare period. If there are <=5 new metastases, a confirmatory scan is performed, and if ...

The 2026 PSMA & Beyond conference featured a developing novel radioligands session and presentation by Dr. Philipp Backhaus discussing the initial experience with APC3. The history of ACP3 goes back ...